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ABSTRACT
In this study, we tested whether polymorphisms in human leukocyte antigen 
G (HLA-G) were associated with event-free survival (EFS) in pediatric Hodgkin’s 
lymphoma (HL). We evaluated the association of HLA-G 3’-UTR polymorphisms with 
EFS in 113 pediatric HL patients treated using the AIEOP LH-2004 protocol. Patients 
with the +3027-C/A genotype (rs17179101, UTR-7 haplotype) showed lower EFS than 
those with the +3027-C/C genotype (HR= 3.23, 95%CI: 0.99-10.54, P=0.012). Female 
patients and systemic B symptomatic patients with the HLA-G +3027 polymorphism 
showed lower EFS. Multivariate analysis showed that the +3027-A polymorphism 
(HR 3.17, 95%CI 1.16-8.66, P=0.025) was an independent prognostic factor. 
Immunohistochemical analysis showed that HL cells from patients with the +3027-
C/A genotype did not express HLA-G. Moreover, HLA-G +3027 polymorphism improved 
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EFS prediction when added to the algorithm for therapeutic group classification of 
pediatric HL patients. Our findings suggest HLA-G +3027 polymorphism is a prognostic 
marker in pediatric HL patients undergoing treatment according to LH-2004 protocol.
INTRODUCTION
Hodgkin lymphoma (HL) originates mostly from 
transformed B-lymphocytes and represents 6% of the 
childhood tumors [1]. Mononuclear Hodgkin (H) and 
multinucleated Reed-Sternberg (HRS) tumor cells 
represent 0.1%–2% of the total tumor infiltrating cells [2]. 
A substantial number of HL cases are linked to Epstein-
Barr virus (EBV) [3]. A follow-up clinical study of the 
Italian Association of Pediatric Hematology-Oncology 
(AIEOP) trial LH-2004 for pediatric HL showed that 
108 out of 769 (14%) enrolled children showed disease 
progression or relapse (37 progression and 71 relapses), 
in general 2 years after diagnosis [4]. Therefore, it is 
important to identify markers that predict relapse in HL 
patients in order to obtain better responses with less 
aggressive therapy, particularly considering the long term 
adverse effects of HL therapy such as secondary cancer, 
infertility and neurological toxicity [5]. Genetic instability 
is also associated with HL. Therefore, it is key to identify 
genetic factors that are involved in HL pathogenesis and 
response to therapy [6-7].
Class I histocompatibility leukocyte antigen (HLA) 
molecules play an important role in the ability of tumor 
cells to evade immune surveillance [8]. Moreover, natural 
killer cells (NK) that kill cancer cells expressing HLA class 
I, are locally inhibited in HL [9-10]. Therefore, antigen-
presentation by the HLA complex and co-stimulatory 
molecule expression plays a key role in the etiology of 
HL, including familial aggregation and the epidemiology 
of HL [11-15]. However, it is unclear if HLA genes are 
associated with HL due to high degree of polymorphism, 
peculiar genomic distribution and high level of linkage 
disequilibrium (LD) among the HLA genes [16].
HLA-G is a non-classical HLA class I molecule 
that is expressed in physiologic conditions in immune 
privileged tissues (e.g. cornea, thymus, pancreatic islets, 
endothelial cell precursors, and erythroblasts) [17]. The 
alternate splicing of HLA-G transcript generates seven 
different mRNAs that give rise to four membrane-bound 
(HLA-G1, G2, G3 and G4) and three soluble (HLA-G5, 
G6 and G7) proteins [18-21]. Both membrane-anchored 
and soluble HLA-G forms generate strong inhibitory 
signals after interaction with their cognate receptors ILT2, 
ILT4 and KIR2DL4, which are differentially expressed 
by NK, T cells, and antigen-presenting cells [22]. HLA-G 
coding region has limited variability except for the 
5’upstream regulatory region (5’UTR) [23] and the 3’ 
untranslated region (3’ UTR) [24], both of which influence 
the HLA-G expression. HLA-G plays an important role 
in maintaining immune tolerance during pregnancy [17]. 
HLA-G is induced during transplantation [25, 26], viral 
infection [27] and malignancies [28, 29] and its expression 
correlates with the size and aggressiveness of solid tumor 
[30, 31]. HLA-G is also expressed by immune cells in 
the tumor microenvironment by trogocitosis, thereby 
restricting their local proliferation and cytotoxicity [32]. 
Furthermore, its expression is regulated by several factors 
such as IL-10, IFN-γ, heat shock, hypoxia, oxidative 
stress and radiation, which further impacts immune 
response towards tumor and tumor-infiltrating cells [33]. 
HLA-G expression and its clinical significance has been 
extensively investigated in solid tumors, but its role in 
hematological malignancies has not been well established 
[34]. Many differences have been reported between 
solid and hematological cancers. These differences are 
probably because immune cells, unlike epithelial cells, 
express both HLA-G and HLA-G receptors (ILT2) that 
inhibit proliferation of B-cell lymphomas, myelomas, 
and B-cell leukemia [35]. HLA-G expression in classic 
HL patients has been investigated in 2 studies both 
regarding adult patients. These authors showed about 
50% of positive- tumor cells for HLA-G expression and 
suggested that induction of HLA-G protein contributed to 
the modulation of immune responses observed in HL since 
HLA-G expression correlated with a better prognosis [36, 
37]. Thus, in hematological diseases, the role of HLA-G 
is more complex than in solid tumors and depends on the 
balance between inhibition of anti-tumor responses and 
the anti-proliferative effects on malignant B cells [28, 
35]. Since it is important to understand the significance 
of HLA-G expression in hematological malignancies, 
we investigated the association of HLA-G 3’-UTR 
polymorphisms with event-free survival (EFS) in pediatric 
HL patients.
RESULTS
Patient and disease characteristics
Patient and disease characteristics are listed in 
Table 1. The HL patients were sub-divided into classical 
HL subtypes such as nodular sclerosis (cHL-NS n=86), 
mixed cellularity (cHL-MC, n=7), nodular lymphocyte-
predominant (HL-LPn, n=9) and unspecified (HL, 
n=11) according to the WHO guidelines [38]. The 
median follow-up period was 3.5 y. Based on Ann Arbor 
staging, patients were subdivided into stages I (n=7), 
II (n= 54), III (n=22) and IV (n=30). Twenty-seven 
patients (24%) showed relapse or tumor progression 
during the follow-up and two patients (1.7%) developed 
secondary tumor.
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Table 1: Demographic and clinicopathological characteristics of HL patients
Characteristics Total N. of patients
(n =113) (%)
Age at diagnosis, years
 Median 13.5
 Range 3-18
 Mean 13.2
Sex
 Female 45 (40)
 Male 68 (60)
WHO classification
 HL-LPn 9 (8)
 cHL-NS 86 (76)
 cHL-MC 7 (6)
 HL 11 (10)
Symptoms
 A 54 (48)
 B 59 (52)
Secondary tumor
 Yes 2 (2)
 No 111 (98)
Ann Arbor Staging
 I 6 (5)
 II 54 (48)
 III 22 (20)
 IV 31 (27)
Therapeutic risk group
 1 17 (15)
 2 16 (14)
 3 80 (71)
Treatment outcome
 Complete remission 86 (76)
 Events (progression or relapse) 27 (24)
Tumor released
 YES 22 (19)
 NO 91 (81)
Observation time
 Mean 4.58
 Median 3.54
 Range 0.19-16.48
HL-LPn=nodular lymphocyte predominant type; cHL-NS=nodular sclerosis; cHL-MC=mixed cellularity; HL= HL not 
easily classified.
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Table 2: Association of HLA-G 3’UTR polymorphisms with gender and clinicopathological characteristics of 
pediatric HL patients
GENDER Female
n= 45 (%)
Male
n= 68 (%)
OR
(95% CI)
P
+3187A/G
 A 53 (59) 101 (74) 1.00 0.016
 G 37 (41) 35 (26) 0.49 (0.28-0.89)
 AA 15 (33.3) 38 (55.9) 1.00 0.018
 AG+GG 30 (66.7) 30 (44.1) 0.39 (0.18-0.86)
Treatment outcome (tumor 
relapse) Event (No) Event (Yes)
OR
(95% CI) P
+3010C/G
 C 91 (51) 30 (68) 1.00 0.027
 G 89 (49) 14 (32) 0.45 (0.21-0.94)
 CC+CG 69 (76.7) 21 (95.5) 1.00 0.025
 GG 21 (23.3) 1 (4.5) 0.16 (0.02-1.23)
+3027C/A
 C 170 (94) 37 (84) 1.00 0.026
 A 10 (6) 7 (16) 3.13 (0.10-8.94)
 CC 82 (91.1) 15 (68.2) 1.00 0.010
 AA+CA 8 (8.9) 7 (31.8) 4.78 (1.51 -15.17)
+3142C/G
 C 92 (51) 30 (68) 1.00 0.031
 G 88 (49) 14 (32) 0.45 (0.21-0.95)
 GG+CG 70 (77.8) 21 (95.5) 1.00 0.032
 CC 20 (22.2) 1 (4.5) 0.17 (0.02 -1.32)
Ann Arbor Stages Stage I Stage II Stage III Stage 
IV
P*
+3196C/G
 C 8 (66.7) 72 (66.7) 28 (63.6) 52 
(83.9)
0.033
 G 4 (33.3) 36 (33.3) 16 (36.4) 10 
(16.1)
 CC 2 (33.3) 24 (44.4) 10 (45.5) 20 
(66.7)
0.021
 CG+GG 4 (66.7) 30 (55.6) 12 (44.5) 10 
(33.3)
OR=odds ratio; 95%CI=95% confidence interval.
P* chi-square test for trend.
CTRL: controls of individuals without hematological malignancies.
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HLA-G +3027 polymorphism is associated with 
EFS after AIEOP LH-2004 treatment
As shown in Supplementary Table 1 the genotype 
and allele frequencies of eight 3’UTR HLA-G 
polymorphisms [14-bp ins/del (rs371194629), +3003C/T 
(rs1707), +3010C/G (rs1710), +3027C/A (rs17179101), 
+3035C/T (rs17179108), +3142C/G (rs1063320), 
+3187A/G (rs9380142) and +3196C/G (rs1610696)] 
were similar in control subjects or blood donors 
Figure 1: Kaplan-Meier survival analysis of +3027C/A HLA-G polymorphisms. Kaplan Meier survival curves show 72.3% 
and 34% EFS for patients with the +3027 C/C and C/A variant, respectively (C/A vs. C/C, HR=3.23, 95% CI 0.99-10.54; P=0.012). The 
solitary patient with A/A genotype was excluded from the analysis.
Table 3: Univariate and multivariate Cox regression analysis of +3027 HLA-G polymorphism as a risk factor in 
pediatric HL patients
Variable Univariate analysis Multivariate analysis
P-value HR 95%CI P-value HR 95%CI
+3027 HLA-G
C/C -- 1.00 -- -- 1.00 --
C/A 0.006 3.23 1.415 - 7.36 0.0251 3.17 1.16-8.66
CI=confidence interval; HR=1.00 for reference category.
The following co-variables were tested: +3010, +3027, +3142 polymorphisms, gender, age, histological WHO classification 
and AIEOP LH-2004 classification for treatment response.
The +3027 A-variant or the UTR-7 haplotype encompasses the 14bp region that spans the Ins, +3003T, +3010C, +3027A, 
+3035T, +3142G, +3187A and +3196C polymorphic sites. Only significant results obtained in multivariate analysis were 
reported.
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(BD; n=259) and HL patients (n=113). In the control 
subjects, there were no differences in the allele and gene 
frequencies based on age or gender for any of the eight 
polymorphisms (data not shown). However, subgroup 
analysis of HL patients by (i) gender showed that male 
gender was associated with the +3187-AA genotype, (ii) 
the +3010-CC+CG; +3027-AA+CA and +3142-GG+CG 
genotypes were associated with increased risk for EFS, 
(iii) the +3196-CC genotype correlated with higher Ann 
Arbor stages (Table 2).
We observed that the +3010-C, +3027-A and +3142-
G alleles were part of the unique 3’-UTR-7 haplotype 
of HLA-G encompassing the +3027-A variant [24]. 
Therefore, we chose the +3027 polymorphism rather than 
UTR-7 haplotype for further analysis.
We found that 27 (23.9%) of the 113 patients that 
received AIEOP LH-2004 treatment experienced a tumor-
event in 1.2±1.048 y (range 0.4-6 y) after diagnosis. 
Kaplan Meier survival analysis demonstrated that the 
patients carrying the heterozygous +3027-C/A genotype 
showed lower EFS time than patients carrying the C/C 
genotype (HR=3.23, 95%CI: 0.99-10.54; P=0.012; Figure 
1). Only 1 out of 113 patients carried the A/A genotype 
and were excluded from the analysis.
HLA-G +3027 A variant is an adverse 
independent risk factor for EFS
Multivariate analysis by Cox proportional hazard 
regression for HLA-G polymorphisms (+3010, +3027, 
+3142, gender, age and therapeutic group classification) 
demonstrated that +3027-A polymorphism (UTR-7 
haplotype) was an independent prognostic factor for poor 
EFS (P=0.025; HR=3.17, 95% CI: 1.16-8.66; Table 3). 
Moreover, female gender and systemic B symptoms in 
combination were associated with poor EFS in pediatric 
HL patients with the +3027 A (UTR-7) haplotype 
(Figure 2).
Inclusion of HLA-G +3027 polymorphism 
enhances EFS risk estimation by the clinical 
therapeutic group (GR)
According to the AIEOP LH-2004 criteria, patients 
were stratified into 3 therapeutic groups (GR) based on 
increased radiation dosage and aggressive chemotherapy 
(both length and intensity) to reduce long-term toxicities 
in younger patients [4]. The groups according to AIEOP 
LH-2004 risk score criteria were (1) GR1: stage IA or IIA 
Figure 2: Cox regression analysis of event-free survival based on gender and systemic symptoms. Cox regression analysis 
shows patients carrying +3027 HLA-G polymorphism show lower EFS in (A) female and (B) systemic B symptomatic patients.
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Figure 3: Kaplan Meier survival analysis comparing algorithms based on the HLA-G genotype and AIEOP LH-2004 
risk score classification. (A) Kaplan Meiersurvival curves based on HLA-G +3027 algorithm is shown. Patients were divided into 2 
groups based on their HLA-G +3027 genotype (C/C and C/A) and further divided into 3 groups based the AIEOP LH-2004 therapeutic risk 
score (GR). Since the GR1 and GR2 groups with the +3027 C/A variant included less than 2 patients, GR1, GR2 and GR3 groups with the 
+3027 C/A variant were merged to form a unique GR123-C/A group. (B) Kaplan Meier survival curves based on the AIEOP LH-2004 risk 
score for therapeutic response (GR) in pediatric HL patients. Note: Criteria for the AIEOP LH2004 therapeutic group (GR) classification 
are in the methods section.
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without mediastinal bulky disease or involvement of lung 
hilum lymph nodes, and less than four lymph nodal regions; 
(2) GR2: negative for GR1 or GR3 criteria; (3) GR3: stage 
IIIB or stage IV or mediastinal bulky disease. Therapy was 
performed based on interim or post-chemotherapy positron 
emission tomography (PET) analysis by quantitative 
Fluorodeoxyglucose (FDG) avidity of tumor mass.
In the present study, we included the HLA-G 
+3027 risk factor in the algorithm with the AIEOP LH-
2004 GR score to predict the EFS risk (Figure 3A). We 
performed Kaplan-Meier analysis of this new algorithm 
and compared it to AIEOP LH-2004 GR score alone 
(Figure 3B). Since the GR1 and GR2 groups included less 
than 2 patients with +3027 C/A variant, we merged the 
GR1, GR2 and GR3 groups with the +3027 C/A variant as 
a unique GR123-C/A group. We stratified patients in the 
4 categories with lower EFS by the presence of +3027-
C/A genotype as shown in the Kaplan-Meier analysis 
(Figure 3). Based on the +3027 genetic algorithm, 8 out of 
15 patients (53%) with the +3027-C/A genotype, and 18 
out of the 68 patients (26%) in the GR3 category showed 
lower EFS (≤2years). We compared the hazard ratio (HR) 
values obtained for both AIEOP LH-2004 GR and HLA-G 
+3027 algorithms and found better risk stratification with 
the HLA-G +3027 algorithm (Figure 4).
Overall survival estimates based on the HLA-G 
+3027 algorithm
Cox regression analysis showed that patients in the 
GR123-C/A and GR3-C/C groups were associated with 
decreased overall survival and lower EFS score according 
to the HLA-G +3027 algorithm (Figure 5). Nine of the 113 
patients that died belonged to the GR123-C/A and GR3-
C/C groups.
Analysis of HLA-G Expression in malignant cells
Immunohistochemical analysis of HLA-G 
expression in tumor cells from 25 lymph node biopsies 
that were obtained at diagnosis showed that patients 
carrying a +3027 C/A genotype were all negative for 
HLA-G and only 5 cases having the wild type +3027 C/C 
genotype showed HLA-G expression (20%; Figure 6).
DISCUSSION
In this study, we showed that the +3027-A (UTR-7 
haplotype) HLA-G polymorphism was associated with a 
low EFS in pediatric HL patients treated according to the 
AIEOP LH-2004 protocol, more evident in female gender 
Figure 4: Comparison of the risk values based on AIEOP LH-2004 group therapy protocol and HLA-G +3027 
algorithm. Kaplan-Meier survival analysis show hazard ratios (HR) for GR1, GR2 and GR3 groups based on AIEOP LH-2004 therapy 
and the HLA-G genetic groups, GR1,2,3-C/C and GR123-C/A based on our analysis. Note: GR1 and GR 1-C/C as reference categories; 
95% CI confidence intervals are shown for event-free survival (EFS).
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and patients with systemic B symptoms. Multivariate 
analysis demonstrated that +3027-C/A genotype was an 
independent prognostic factor associated with poor EFS. 
Moreover, incorporating the HLA-G +3027 polymorphism 
into the AIEOP LH-2004 therapeutic stratification 
improved risk evaluation. Patients belonging to the 
GR123-C/A and the GR3 groups showed lower 5 year-
overall survival than patients belonging to GR1 and GR2 
groups (9.7% vs. 0%). The effect of HLA-G expression on 
HL patient survival needs further investigation.
Many studies have reported association of 
polymorphisms in the HLA region with HL [39, 40]. 
However, the association of variants in the 3’UTR of 
HLA-G with clinical outcome in HL has not been reported 
so far. Moreover, mechanisms that regulate HLA-G 
expression in B-cells are not well defined [37, 41, 42]. 
We demonstrated that HLA-G was not expressed in the 
tumor cells of HL patients with +3027-C/A genotype and 
present only in a minority of cases (20%) with the wild 
type +3027-C/C genotype. Previously, HLA-G expression 
was reported in adult HL patients belonging to Ann Arbor 
stages IIb-IV in the tumor microenvironment in patients 
showing positron emission tomography (PET)-positive 
(carried out after 2 cycles of standard chemotherapy) 
during follow-up [37]. Conversely, PET-negative patients 
showed higher HLA-G protein expression levels on 
tumor cells (50% of cases) suggesting that HLA-G 
protein expression inhibited tumor progression [37]. 
We demonstrated that HLA-G was not expressed in the 
lymph node of HL patients carrying the HLA-G +3027 
C/A genotype. However, HLA-G was expressed in few 
cases (n=5) with +3027 C/C genotype and therefore, the 
role of the wild type HLA-G C/C genotype needs to be 
studied in greater detail. Caocci et al. showed that HLA-G 
expression was a positive prognostic factor in patients 
with advanced-stage classical HL [37]. In the present 
study, we found HLA-G-positive tumor cells in lower 
number of cases (n=5/25, 20%) than reported by Diesptra 
Figure 5: Overall survival in pediatric HL patients based on therapeutic grouping. Cox regression analysis showing OS 
in pediatric HL patients (n=113) based on therapeutic grouping (GR). As shown, GR1-C/C and GR2- C/C patients show higher EFS than 
GR3-C/C and GR123-C/A patients.
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et al. and Caocci et al. (about 55%). However, all of our 
HLA-G-positive cases demonstrated positive prognosis 
as reported earlier. Patients that carried the +3027 C/A 
variant were associated with poor prognosis and were all 
HLA-G-negative.
HLA-G expression can exert beneficial or 
detrimental effects of immune recognition, which 
depend on the pathological context or situation [34, 43]. 
HLA-G expression suppresses immune response in case 
of allotransplantation and autoimmune disorders [44]. 
However, HLA-G expression would be detrimental in 
solid tumors and virally infected cells, where it suppresses 
immune response by inhibiting NK cells that kill tumor 
cells [45]. Correlation between HLA-G expression and 
clinical outcome in hematological malignancies is unclear 
[46]. One probable reason is that contrary to epithelial 
cells, immune cells express both HLA-G and its inhibitory 
receptors such as ILT-2 on their surface. In multiple 
myeloma and B-cell leukemia, interaction with HLA-G 
and ILT2 inhibitory receptor induces tumor cell apoptosis 
[35]. Moreover, since the HLA-G +3027-A variant was 
found associated with lower HLA-G expression [41], 
our data might suggest that patients with the +3027-C/A 
genotype are more prone to tumor relapse because more 
prone to decreased expression in HLA-G, which affects 
HL tumor cell apoptosis.
Of note, the impact of chemotherapy and 
radiotherapy on HLA-G expression in patients carrying 
the HLA-G +3027-C/C and the HLA-G +3027-C/A 
genotypes is not known. Previous reports have shown 
that gamma radiation and/or chemotherapy modulates 
surface HLA-G expression in B-cell lines (M8 and K562), 
melanoma cell lines (OCM-1A and JEG-3) and basal cell 
carcinoma of the skin [47, 48]. Thus, it is possible that 
chemo/radiotherapy modulate HLA-G expression also in 
our patients having a good prognosis, but not in patients 
having the HLA-G +3027 C/A genotype for a reason still 
now unknown.
However, it is also possible that +3027-C/A 
polymorphism could be in strong linkage disequilibrium 
Figure 6: Immunohistochemical analysis of HLA-G protein expression in Reed-Sternberg cells in pediatric HL 
patients. Representative image shows immunohistochemical staining for HLA-G in a HL patient carrying the wild type C/C +3027 
genotype. Formalin/PFA-fixed paraffin-embedded sections were stained with primary anti-HLA-G antibody (4H84). Lymphoma cells show 
strong membrane staining for HLAG. Note: Only 5 out of 25 patients analyzed were positive for HLA-G in our analysis.
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with another critical gene, which causes the disease 
progression and poor EFS.
Overall these issues needs to be investigated in 
detail.
In conclusion, we demonstrated that +3027-A 
HLA-G polymorphism was associated with poor EFS in 
pediatric HL patients treated with the AIEOP LH-2004 
protocol. In the future, comprehensive prospective studies 
are necessary to confirm that HLA-G polymorphisms are 
prognostic indicators in pediatric HL therapy.
MATERIALS AND METHODS
Sample collection and Patient grouping criteria
Peripheral blood samples were collected from 
113 pediatric HL patients (range 3-18 years) at the 
AIEOP Centers in the laboratory of Padua University 
from December 2004 to August 2014. Table 1 lists 
patient information regarding age, sex, the presence of a 
secondary tumor, relapse and/or progression tumor events, 
presence or absence of systemic symptoms and Hodgkin’s 
lymphoma subtype as recommended by World Health 
Organization (WHO) [38]. The patients were also staged 
according to Ann Arbor classification [48] and allocated 
into 3 therapeutic groups (GR) based on risk [4]. These 3 
groups were (1) GR1: stage IA or IIA without mediastinal 
bulky disease or involvement of lung hilum lymph nodes, 
and with less than four lymph nodal regions; (2) GR2: 
absence of criteria for GR1 or GR3; and (3) GR3: stage 
IIIB or stage IV or mediastinal bulky disease. The patients 
were treated according to the protocol approved for the 
AIEOP multicenter clinical trial LH-2004 [4].
Treatment protocol and follow-up
The GR1 patients (low risk) were administered 3 
cycles of ABVD (Adriamycin, bleomycin, vinblastine, 
dacarbazine) without radiotherapy (RT) were 
administrated. In case of unsatisfactory response after 
2 cycles of ABVD or residual disease after 3 cycles, 
GR1 patients received chemotherapy/RT or RT. The 
GR2 (intermediate risk) and GR3 (high risk) patients 
were administered 4 or 6 alternating cycles of COPP-
ABV chemotherapy (cylcophosphamide, vincristine, 
procarbazine, prednisone and ABV) to ABVD treatment. 
Radiotherapy was administered with Involved Field 
Technique (IFRT) at cumulative dose of 14.4 or 25.2 Gy 
depending on the remission status (complete or partial) at 
the end of chemotherapy. Patients in complete remission 
at the end of chemotherapy were not administered 
radiotherapy. Complete response (CR) was defined as 
absence of clinical, radiological (ultrasound and/or CT 
scan evaluation) and FDG-PET evidence of disease. 
We enrolled 259 local blood donors (BD) as a control 
group. Study was approved by the ethics committee of 
all participating institutions. Written consent forms were 
obtained from parents or legal guardians of all patients.
HLA-G genotyping
Genomic DNA was extracted from peripheral blood 
with the Qiagen DNAeasy Kit (QIAGEN, Grand Island, 
NY). HLA-G genotyping was performed by first PCR 
amplifying using the 3’UTR specific primers (forward, 
5’-TGTGAAACAGCTGCCCTGTGT-3’ and reverse, 
5’-GTCTTCCATTTATTTTGTCTCT-3’) [24] followed 
by Direct BigDye Terminator sequencing. The data was 
analyzed with the Assign SBT software version 3.27b 
(Conexio Genomics, Fremantle, Western Australia) [49]. 
All polymorphic sites were individually annotated.
Immunohistochemistry
Paraffin-embedded primary HL lymph node tissue 
was retrieved. HLA-G expression was assessed in 25 
paraffin-embedded tissues by Immunohistochemical 
staining with primary 4H84 mouse monoclonal antibody 
(Abcam, HIER, 1:2000), which recognizes all the HLA-G 
isoforms. If intense membrane HLA-G staining was found 
in more than 10% of Hodgkin or Reed-Sternberg cells, 
then the sample was scored as positive.
Statistical analysis
The frequencies of HLA allele and genotype were 
compared between patients and controls chi-square test 
(VassarStats http://faculty.vassar.edu/lowry/VassarStats.
html and the SKDM software (http://sourceforge.net/
projects/skdm). The HLA-G 3’UTR haplotypes were 
defined according to Castelli [50]. HLA haplotype 
frequencies were estimated by the ARLEQUIN ver 3.1 
software [51]. Frequencies and distributions of clinical 
characteristics were calculated as the period of time 
after diagnosis. Kaplan-Meier survival analysis was 
performed to determine relapse rate and overall survival 
after diagnosis and treatment according to the LH-2004 
protocol. We included age, gender, Ann Arbor stage, 
tumor response, presence of systemic symptom and WHO 
histopathological classification as potential co-variables 
in the univariate model. Multivariate Cox proportional 
hazards models were used to estimate hazard ratios (HRs) 
for EFS with 95% CIs adjusted for +3027 polymorphism 
and potential co-variables. The most frequent variable was 
automatically selected as the reference category. Clinical 
prognostic risk groups [4] currently used to stratify 
therapy were used to compare the +3027 HLA-G genetic 
stratification.
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